Defiance ETFs Launches Autism Impact Fund
The new investment vehicle tracks companies involved in autism research and support while pledging profits to related causes.
Updated on Oct. 16, 2026 in Autism
Live Poll
Would you consider investing in a fund that prioritizes charitable donations over maximum financial return?
In June 2026, Defiance ETFs launched the Autism Impact ETF to provide investment exposure to firms focusing on pharmaceuticals, diagnostics, and behavioral health. The fund currently manages approximately $1.35 million in assets and tracks the VettaFi Autism Impact Index.
Why it matters
The fund issuer developed this investment product based on the CEO's personal family experience with an autism diagnosis. By allocating capital to specialized service providers, the fund aims to align financial goals with support for the autism community.
The fund maintains a 0.79% expense ratio and holds a portfolio of approximately 40 companies. Meanwhile, a pharmaceutical drug included in the sector tracking reported a 53% efficacy rate in a recent Phase 2 clinical trial.
The players
Defiance ETFs
Defiance ETFs is a financial firm that specializes in thematic exchange-traded funds.
VettaFi
VettaFi is a data and index provider that develops specialized benchmarks for the financial industry.
The details
The ETF invests in a range of sectors including pharmaceuticals, behavioral health, diagnostics, and specialized education. Defiance has committed to donating 100% of its net advisory profits for the first two years, shifting to at least 50% thereafter.
Timeline
Defiance ETFs launched the Autism Impact ETF in June 2026.
Health Landscape
The Autism Impact ETF follows the benchmark set by the VettaFi Autism Impact Index to offer targeted exposure to medical and behavioral services. This development signals a shift toward impact-focused investment products that link retail financial assets with specialized health research milestones.
The fund directs a significant portion of its net advisory profits toward autism-related organizations, potentially impacting the availability of resources and community support services. Investors should consider the 0.79% expense ratio as part of their personal financial strategy when evaluating this thematic fund.
The takeaway
This fund represents a growing trend of thematic investing where financial returns are directly linked to charitable contributions for specific medical causes. Investors interested in this space should review the fund prospectus to understand how the 0.79% expense ratio impacts their long-term holdings.
Further reading
For broader insights into how investment and medical support sectors are intersecting, see the Autism section.
Live Poll
Would you consider investing in a fund that prioritizes charitable donations over maximum financial return?
